Trials / Completed
CompletedNCT01394562
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure
Multicentre, Prospective, Randomised, 2-arm Study to Assess the Impact of Ferric Carboxymaltose on Exercise Capacity in Chronic Heart Failure Patients With Iron Deficiency
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 174 (actual)
- Sponsor
- Vifor Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm that treatment with IV ferric carboxymaltose improves exercise capacity, physical functioning and quality of life in patients with iron deficiency and chronic heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ferinject (ferric carboxymaltose) | Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12 |
| OTHER | Standard of Care | Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2011-07-14
- Last updated
- 2017-05-18
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01394562. Inclusion in this directory is not an endorsement.